Cushing's syndrome from an inhaled glucocorticoid.
OBJECTIVE
To report a case of significant systemic side effects from an inhaled glucocorticoid at a reported dose in the upper recommended therapeutic range.


METHODS
A 25-year-old white man with asthma treated with inhaled glucocorticoid (beclomethasone 1500 micrograms daily), and primary testicular failure with inadequate androgen replacement, was referred with back pain. He was found to have osteoporosis, clinical features of Cushing's syndrome and complete suppression of endogenous adrenocorticotrophic hormone adrenal function.


RESULTS
He was recommended to receive adequate androgen replacement and to use a spacer device with the inhaled beclomethasone, or to change to budesonide via a Turbuhaler (AB Astra, Sweden).


CONCLUSIONS
Inhaled glucocorticoids should not be regarded as entirely safe, as serious systemic side effects may occur at doses at the upper level of the recommended therapeutic range.
Chalkley
S M
SM
Department of Endocrinology, St Vincent's Hospital, Darlinghurst, NSW.
Chisholm
D J
DJ
D000281:Administration, Intranasal; D000328:Adult; D001249:Asthma / Q000188:drug therapy; D001507:Beclomethasone / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003480:Cushing Syndrome / Q000139:chemically induced*; D006801:Humans; D008297:Male
D001507:Beclomethasone